Mesoblast (NASDAQ:MESO) Shares Gap Up – Time to Buy?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $13.54, but opened at $13.97. Mesoblast shares last traded at $13.78, with a volume of 13,626 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Price Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The stock’s 50-day moving average is $16.79 and its 200-day moving average is $12.81.

Institutional Investors Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd acquired a new position in shares of Mesoblast in the 4th quarter valued at $30,000. Barclays PLC acquired a new position in shares of Mesoblast in the 4th quarter valued at $38,000. Lindbrook Capital LLC boosted its position in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Mesoblast in the 4th quarter valued at $50,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after purchasing an additional 2,597 shares during the period. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.